ClinicalTrials.gg
TerminatedNCT02254525Updated Oct 2, 2014

A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain

A Phase 3 interventional study of Intravenous ibuprofen and Saline solution in Postoperative Pain, sponsored by Biomendi S.A.U.. Terminated at 13 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by Biomendi S.A.U. · Phase 3, Interventional, and Treatment

Why this study was terminated
Sample not reached in traumathology arm

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies testing ibuprofen in Pain, Postoperative — 7 open to participants now, 8 under way, none of them phase 3. Ibuprofen · Pain, Postoperative.

Enrollment
9th of 56
231 · median 100
Started
2012
with 1 other
Phase 3
7 of 56
none open now
Registered
12th of 56
by date

Among the 56 studies testing ibuprofen in Pain, Postoperative, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 12th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 56 studies testing ibuprofen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing ibuprofen in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to study the efficacy of intravenous administration of ibuprofen compared to placebo in patients with postoperative pain and evaluate its tolerability and safety profile.

Read the detailed description

This is a phase III, national, multicenter, randomized, double-blind, parallel groups, and placebo-controlled.

Patients will be randomized to receive either ibuprofen or placebo. Stratified randomization will be used to assign eligible patients to a stratum according to type of surgery and centre. Randomization sequence will be generated in the coordinating centre.

Blinding of the patient and study personnel evaluating response will be warranted by adequate drug labelling.

All patients will receive morphine administered by patient controlled analgesia (PCA) following a similar schedule in all centres: 1 mg bolus dose with a close time of 5 min and a maximum of 10 mg in an hour and a maximum of 30 mg in 4 hours.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women between 18 and 80 years old.
  2. Being scheduled for elective single surgical site orthopaedic surgery (hip or knee joint replacement, corsed ligaments, column or shoulder surgery), or abdominal surgery (inguinal hernia, cholecystectomy, eventration or hiatus hernia)
  3. Being scheduled for general anaesthesia or regional anesthesia without regional analgesia after surgery.
  4. Having anticipated need for postoperative narcotic analgesia administered by patient controlled analgesia (PCA).
  5. Expected to stay at the hospital for at least 24 h.
  6. Providing written for participating in this study.

Exclusion criteria

Exclusion Criteria:

  1. Use of NSAID within 12 hours prior to the first planned dose.
  2. Taking oral anticoagulants, lithium, combination of ACE inhibitors, furosemide or aspirin.
  3. Anaemia ( \<10 g/dl) and/or history or evidence of asthma or heart failure.
  4. History of allergy or to any component of IV ibuprofen, aspirin or aspirin related products, NSAID or COX-2 inhibitors.
  5. Pregnant or nursing.
  6. Weight less than 40 kg.
  7. History of severe head trauma that required hospitalization, intracranial surgery or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass lesion.
  8. History of congenital bleeding diathesis or any active bleeding or underlying dysfunction.
  9. Gastrointestinal bleeding that required medical intervention.
  10. Platelet count less than 80.000 determined within the 28 days prior to surgery.
  11. Pre-existing dependence on narcotics or receiving chronic treatment with opioids.
  12. Severe renal failure (calculated \< 60 ml/min).
  13. Liver failure, ALAT or ASAT >3 times upper limit of normality, or >2 g/dl.
  14. Diagnosed of Bowel Inflammatory Disease.
  15. Not able to understand the requirements of the study, or to abide by the study restrictions or to return for the required assessments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    800 mg intravenous ibuprofen

    Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.

    Drug: Intravenous ibuprofen

  • Placebo comparator
    200 ml of saline solution

    Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.

    Drug: Saline solution

Interventions

  • Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.

    Also known as: IV ibuprofen

  • DrugSaline solution

    Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of intravenous ibuprofen for the management of postoperative pain in comparison to placebo

    The primary efficacy endpoint will be the reduction in total morphine use in the first 24 hours post- surgery as compared to placebo.

    Time frame: First 24 hours post- surgery

Secondary outcomes

  1. Secondary efficacy endpoints

    - Consumption of morphine in the first 48 h (and 72) hours post- surgery.

    Time frame: From 0 hours to 72 hours post- surgery

  2. Secondary efficacy endpoints

    - Pain intensity at rest and with movement measured with the eleven points visual analogue scale (VAS), at 1 and 3 hours and every 6 hours thereafter up to hour 24 h, and then every 8 h up to 6 hour after the last ibuprofen dose.

    Time frame: From 0 hours to 72 hours post- surgery

  3. Secondary efficacy endpoints

    - Ramsay-Hunt sedation scale.

    Time frame: From 0 hours to 72 hours post- surgery

  4. Secondary efficacy endpoints

    - Time to first subsequent narcotic analgesia (or time to treatment failure).

    Time frame: From 0 hours to 72 hours post- surgery

  5. Secondary efficacy endpoints

    - Number of doses of morphine and number of attempts of dosing at PCA

    Time frame: From 0 hours to 72 hours post- surgery

  6. Secondary tolerability and safety endpoints

    - Report of adverse events (AEs) during the study

    Time frame: From 0 hours to 72 hours post- surgery

  7. Secondary tolerability and safety endpoints

    - Local reactions due to IV infusion (pain, erythema, phlebitis)

    Time frame: From 0 hours to 72 hours post- surgery

  8. Secondary tolerability and safety endpoints

    - Vital signs (heart rate, blood pressure, temperature) at 1, 3, 6 hour after the initial dose and every 8 hours thereafter.

    Time frame: From 0 hours to 72 hours post- surgery

  9. Secondary tolerability and safety endpoints

    - Routine laboratory tests (chemistry, haematology and coagulation) at baseline and within 24 hours after the last dose.

    Time frame: From 0 hours to 72 hours post- surgery

07

Study locations

13 sites
  • Hospital de Móstoles
    Móstoles, Madrid 28935, Spain
  • Hospital Xeral Cíes de Vigo
    Vigo, Pontevedra 15781, Spain
  • Hospital de Cruces
    Barakaldo, Vizcaya 48903, Spain
  • Complejo Hospitalario Universitario de A Coruña
    La Coruña, 15001, Spain
  • Hospital Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital La Princesa
    Madrid, 28006, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital de Montepríncipe
    Madrid, 28660, Spain
  • Clínica Universitaria de Navarra
    Pamplona, 31008, Spain
  • Hospital Virgen de la Salud
    Toledo, 45005, Spain
  • Hospital La Fe
    Valencia, 46026, Spain
  • Hospital Clínico de Valladolid
    Valladolid, 47005, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Oct 2, 2014
Start
May 2012
Primary completionActual
Jun 2014
CompletionActual
Jul 2014
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02254525
Lead sponsor
Biomendi S.A.U.
Collaborators
Pivotal S.L.
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
May 2012
Primary completion
Jun 2014
Completion
Jul 2014
Last update
Oct 2, 2014

Study contacts

Concepción Pérez, MD
study chair · Hospital La Princesa
Francisco Abad, MD
study chair · Hospital La Princesa
Dolores Ochoa, MD
study chair · Hospital La Princesa
Antonio Planas, MD
study chair · Hospital La Princesa

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion